Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Abstract
  • Supplemental material
  • Version history
  • Article usage
  • Citations to this article
Advertisement

ResearchIn-Press PreviewAgingEndocrinology Open Access | 10.1172/jci.insight.206012

Local growth hormone promotes benign prostatic hyperplasia

Masaki Ryuzaki,1 Svetlana Zonis,1 Neil A. Bhowmick,2 Sandrine Billet,2 Saravana Kumar Kailasam Mani,2 Stephen J. Freedland,3 Hyung L. Kim,3 Vera Chesnokova,1 and Shlomo Melmed1

1Pituitary Center, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, United States of America

2Division of Medical Oncology, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, United States of America

3Department of Urology, Cedars-Sinai Medical Center, Los Angeles, United States of America

Find articles by Ryuzaki, M. in: PubMed | Google Scholar

1Pituitary Center, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, United States of America

2Division of Medical Oncology, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, United States of America

3Department of Urology, Cedars-Sinai Medical Center, Los Angeles, United States of America

Find articles by Zonis, S. in: PubMed | Google Scholar

1Pituitary Center, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, United States of America

2Division of Medical Oncology, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, United States of America

3Department of Urology, Cedars-Sinai Medical Center, Los Angeles, United States of America

Find articles by Bhowmick, N. in: PubMed | Google Scholar |

1Pituitary Center, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, United States of America

2Division of Medical Oncology, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, United States of America

3Department of Urology, Cedars-Sinai Medical Center, Los Angeles, United States of America

Find articles by Billet, S. in: PubMed | Google Scholar

1Pituitary Center, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, United States of America

2Division of Medical Oncology, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, United States of America

3Department of Urology, Cedars-Sinai Medical Center, Los Angeles, United States of America

Find articles by Kailasam Mani, S. in: PubMed | Google Scholar |

1Pituitary Center, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, United States of America

2Division of Medical Oncology, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, United States of America

3Department of Urology, Cedars-Sinai Medical Center, Los Angeles, United States of America

Find articles by Freedland, S. in: PubMed | Google Scholar |

1Pituitary Center, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, United States of America

2Division of Medical Oncology, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, United States of America

3Department of Urology, Cedars-Sinai Medical Center, Los Angeles, United States of America

Find articles by Kim, H. in: PubMed | Google Scholar

1Pituitary Center, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, United States of America

2Division of Medical Oncology, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, United States of America

3Department of Urology, Cedars-Sinai Medical Center, Los Angeles, United States of America

Find articles by Chesnokova, V. in: PubMed | Google Scholar

1Pituitary Center, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, United States of America

2Division of Medical Oncology, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, United States of America

3Department of Urology, Cedars-Sinai Medical Center, Los Angeles, United States of America

Find articles by Melmed, S. in: PubMed | Google Scholar

Published July 28, 2026 - More info

JCI Insight. https://doi.org/10.1172/jci.insight.206012.
Copyright © 2026, Ryuzaki et al. This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
Published July 28, 2026 - Version history
View PDF
Abstract

Locally produced nonpituitary growth hormone (npGH) promotes DNA damage accumulation and epithelial-mesenchymal transition (EMT) in aging human colon epithelium. GH receptor (GHR) and npGH are expressed in normal human prostate and benign prostatic hyperplasia (BPH) prevalence increases with age. We hypothesized that local prostate GH action may promote EMT and contribute to BPH pathogenesis. We show here that the number of patients expressing npGH increases >10-fold after age 60, concordant with increased γH2AX, a marker of DNA damage, and EMT activation. GH-treated human primary prostate epithelial cells, normal prostate cells, and primary cell cultures derived from resected BPH specimens exhibited enhanced DNA damage and activated EMT, with induced TWIST2 and suppressed E-cadherin, as well as increased Ki67, cell motility, and proliferation. In mice, prostate tissue adjacent to allografted GH-expressing fibroblasts showed increased γH2AX, TWIST2, and Ki67 compared to controls, along with morphological changes consistent with BPH. While GH and GH-induced IGF-1 both activated EMT, GH triggered DNA damage independent of IGF-1. These results elucidate a novel role for local npGH in aging prostate tissue, whereby npGH increases DNA damage and promotes EMT to enable a microenvironment favoring BPH development. Prostate GHR signaling may be an attractive therapeutic target for BPH.

Graphical Abstract
graphical abstract
Supplemental material

View Unedited blot and gel images

View

Version history
  • Version 1 (July 28, 2026): In-Press Preview

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

  • Article usage
  • Citations to this article

Go to

  • Top
  • Abstract
  • Supplemental material
  • Version history
Advertisement
Advertisement

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts